Search
Chiatai Tianqing Submits IND Applications for Two Class 1 Novel Oncology Drugs in China
2025-08-12 /
Read about 0 minute
Author：小编
Chiatai Tianqing has proudly announced the acceptance of its Investigational New Drug (IND) applications for two pioneering Class 1 novel oncology drugs, TQB3142 and TQB3122, by the National Medical Products Administration (NMPA) of China. TQB3142, specifically designed to target Bcl-xL protein degradation, holds promise for the treatment of malignant tumors. Meanwhile, TQB3122, a highly selective PARP1 inhibitor, also aims to address malignant tumors, underscoring Chiatai Tianqing's commitment to advancing cancer therapeutics.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
